A Phase II Study of Durvalumab Immunotherapy and Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer


Full Title

Stereotactic Body Radiation Therapy with Consolidation Durvalumab in High-Risk Early-Stage Non-Small Cell Lung Cancer - A Phase II Single-Arm Trial


The purpose of this study is to learn whether treatment with the immunotherapy drug durvalumab combined with a type of radiation therapy called stereotactic body radiation (SBRT) is a more effective treatment for inoperable high-risk early-stage non-small cell lung cancer (NSCLC) than SBRT alone. Researchers want to see if adding treatment with durvalumab to SBRT will reduce the chance that a patient’s cancer will get worse. All patients will receive both durvalumab and SBRT.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have inoperable stage I-IIIA NSCLC.
  • Patients must have an estimated risk of 40 percent or higher of the cancer getting worse, based on tumor size and activity on a PET scan.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Andreas Rimner at 646-608-2449.